
bluebird bio Investor Relations Material
Latest events

Q3 2024
bluebird bio

Q1 2025
6 Aug, 2025

Q4 2024
27 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from bluebird bio Inc
Access all reports
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. The company's product portfolio comprises two clinical-stage lentiviral-based gene therapy product candidates for the treatment of transfusion-dependent b-thalassemia (TDT) and severe sickle cell disease (SCD); and a preclinical-stage gene therapy product candidate for the treatment of childhood cerebral adrenoleukodystrophy. Its clinical development programs include LentiGlobin BB305 program to treat TDT and SCD; and Lenti-D that is in Phase II/III trial to treat cerebral adrenoleukodystrophy. The company has collaboration agreements with Celgene Corporation; Intellia Therapeutics, Inc.; Catalent Biologics LLC; Kite Pharma, Inc.; Genethon S.A.; and University of Pennsylvania. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts
Key slides for bluebird bio Inc


Status Update
bluebird bio Inc


Status Update
bluebird bio Inc
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
BLUE
Country
🇺🇸 United States